AzTrials
AzTrials

SmokingNCT02494960

Brief Tobacco Cessation Intervention

A study testing The brief smoking cessation AWARD model in people with Smoking, run by The University of Hong Kong at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Traditional smoking cessation clinics and telephone quitlines are expensive and 'passive' as they require motivated smokers to visit the clinic or make a phone call to seek help. However, in most middle-resource countries, smoking cessation clinics are not well publicized. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Smoking
What is being tested?
The brief smoking cessation AWARD model
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
13,671 participants
Where
1 siteChina
Study dates
Aug 2014to Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Outpatients aged 18 years or above
  • Smoke on at least 1 day in the past 30 days
  • Chinese residents able to communicate in Chinese (Mandarin or Cantonese)
  • Has a telephone

Who cannot join

  • Smokers currently receiving smoking cessation interventions
  • Smokers currently enrolled in other smoking cessation trials
  • Smokers who need special care on quitting and are not suitable for AWARD intervention (determined by his/her doctor)
  • Smokers with communication difficulties (physical or cognitive condition)

Trial locations and contacts

1 site in 1 country.

China1 site
  • 5/F William MW Mong Block, LKS Faculty of Medicine Building, 21 Sassoon Road, Pokfulam

    Hong Kong, Guangdong

Other trials in China

About this study

Official title: Brief Tobacco Cessation Intervention: a Randomized Controlled Trial in Guangdong, China

Traditional smoking cessation clinics and telephone quitlines are expensive and 'passive' as they require motivated smokers to visit the clinic or make a phone call to seek help. However, in most middle-resource countries, smoking cessation clinics are not well publicized. Most health care professionals (HCP) are not active in performing smoking cessation counselling to their patients. They are not aware of the available smoking cessation services or the benefits of such services and hence do not refer smokers to smoking cessation services. On the other hand, physicians play a critical role in reducing tobacco use by advising smoking patients to quit (Richmond, 1999). Physician's advice to quit smoking not only motivates smokers to quit but also increases their quitting confidence (Fiore et al., 2000; Ossip-Klein et al., 2000).

Brief smoking cessation interventions have been shown to be effective with strong evidence from randomized controlled trials (RCTs), however, it is no evidence to show that longer interventions are more effective than shorter interventions. If carried out in routine clinical practice by all physicians and other HCP, brief interventions can potentially benefit a great number of smokers and increase smoking cessation rate. Therefore, we propose to examine the effect of a brief smoking cessation counselling intervention (10-20 seconds AWARD model) among patients using a randomized controlled trail (RCT) design in Guangdong province, China

This project aims to evaluate the effect of physicians' brief smoking cessation intervention (AWARD model) in real busy clinic settings using a randomized controlled trial (RCT) design.

Read the detailed description

Smokers will be recruited from the internal medicine outpatient clinics at the participating hospitals (the general nonprofit public hospitals) and community health centers. Same as the pilot study, trained doctors will ask all visiting patients during clinic consultation whether they smoke, confirm eligibility, provide information sheet and seek oral agreement to be followed up by telephone after clinic consultation. If eligible and oral consent obtained, the doctor will fill the recruitment form.

The doctors will randomly allocate the enrolled patient into intervention or control group using SNOSE method. This method will ensure allocation concealment. If the patient refuses to participate, the doctor will note on the summary form. Enrolled patients' medical records will be marked with a sticker (red for intervention group, green for control group) so they will not be recruited again if they come back to the participating hospital.

At the end of each clinic session, the doctors will immediately fill the rest part of the summary form and send the recruitment form and summary form to trained research assistants by email or WeChat. The research assistants will enter all information into a web-based or app-based study management system (SMS) using tablet PC.

For smokers in intervention group, the doctor will offer a brief (10-20 seconds) WAR smoking cessation intervention (Warn the smokers that at least one out of two smokers will be killed by smoking, and according to WHO, two out of three smokers will be killed by smoking; Advice the smokers to quit now or as soon as possible; and Refer the smokers to a smoking cessation clinic or telephone quitlines by offering a referral card which contains the contact information of the smoking cessation clinics and/or quitlines as well as a pictorial information leaflet which explains the risks of smoking). For control group, the doctor will offer a brief (10-20 seconds) placebo intervention (Advice the smokers to eat vegetables, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day).

Within 3 days after enrolment (T1), study personnel will call the participants using the tablet PC with questionnaire program to invite them to complete a short baseline survey.

At 1-month FU (T2), study personnel will call the participants using the tablet PC with questionnaire program to assess his/her smoking and quitting outcomes. After the assessment, trained study personnel will get the information about the participants' group status from the tablet PC. For Group C, the trained study personnel will end the phone call without further assessment or intervention. For Group I, the trained study personnel will use the tablet PC to randomly assign the participant to Group I-A or I-B.

For Group I-A, trained study personnel will repeat the brief (10-20 seconds) AWARD intervention (Warn the smokers that at least one out of two smokers will be killed by smoking, and according to WHO, two out of three smokers will be killed by smoking; Advice the smokers to quit now or as soon as possible; and Refer the smokers to a smoking cessation clinic or telephone quitlines by offering the contact information of the smoking cessation clinics and/or quitlines); for Group I-B, trained study personnel will end the phone call without further questions or actions.

At 3-month FU (T3), study personnel will use the programmed tablet PC to call participants and measure his/her smoking patterns and quitting efforts.

At 6- and 12-month FU (T4\&T5), study personnel will use the programmed tablet PC to call participants and measure his/her smoking patterns and quitting efforts again. Participants who report that they have been abstained from nicotine for ≥7 days will be invited to complete biochemical validation in clinics. Exhaled CO less than 4ppm and salivary cotinine less than 10ng/ml tested by NicAlert® strips (www.nymox.com) will be treated as validated abstinence. If for any reason, the participants are not able to complete the biochemical validation, study personnel will use the programmed tablet PC to conduct a non-biochemical validation survey to validate whether or not the participants have been abstained from nicotine.

Study personnel will always be blinded to participants' group status at follow-up interviews (single blinded). Subjects will be randomly allocated to study personnel for follow-up interviews, so subjects are likely to be interviewed by different study personnel in this study.

T-test will be conducted to compare the primary (a) outcomes and the secondary outcomes. Separate multivariate logistic regression model will be performed for each of the three groups (i.e., I-A, I-B, and C) between the baseline and the 12-month follow-up, controlling for age, gender, education, and income to determine whether the outcome of interests (quitting rate and smoking reduction rate) had increased, remained unchanged, or decreased. Change (e.g., increase or decrease) will be considered significant if p <.05.

Multivariate logistic regression models will also be used to examine if the smoking cessation intervention is associated with successful quitting and smoking reduction, as well as other factors (e.g., demographic variables) associated with successful quitting and smoking reduction.

Sensitivity test based on the result of physicians' fidelity check will be conducted to determine the effect of the physician's very brief smoking cessation counselling on quitting and smoking pattern changes. The fidelity check will evaluate the adherence of physicians' implementation to the study protocol.

Conditions
Smoking
Being tested
The brief smoking cessation AWARD model, Placebo intervention
Keywords
smoking cessation intervention
Medical subject headings
Smoking

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • The brief smoking cessation AWARD modelBehavioural

    • Ask whether or not the patient currently smokes
    • Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.
    • Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.
    • Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.
    • Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again.
  • Placebo interventionBehavioural

    Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day

Study groups in NCT02494960
Study groupRoleWhat they receive
Control GroupPlacebo comparatorThe doctor will offer a placebo intervention.
Receives: Behavioral: Placebo intervention
Intervention Group AExperimentalThe doctor will offer the brief smoking cessation AWARD model . At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model .
Receives: Behavioral: The brief smoking cessation AWARD model
Intervention Group BExperimentalThe doctor will offer the brief smoking cessation AWARD model.
Receives: Behavioral: The brief smoking cessation AWARD model

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Smokers' self-reported 7-day point prevalence quitting rate

    Self-reported tobacco abstinence in the past 7 days

    Measured: up to 12-months follow-up

Secondary outcomes (7)
  1. Biochemically validated quit rate

    Tobacco abstinence validated by exhaled carbon monoxide (<4ppm) and saliva cotinine (<10ng/ml)

    Measured: 6- and 12-months follow-up

  2. Non-biochemically validated quit rate

    Tobacco abstinence verified by the interviewers

    Measured: 6- and 12-months follow-up

  3. Self-reported sustained nicotine abstinence

    Self-reported tobacco abstinence in the past 30 days

    Measured: 1- and 3-month follow-up

  4. Smoking reduction (cigarette or other tobacco product use decreased by at least 50%) among continuing smokers

    Smoking reduction (cigarette or other tobacco product use decreased by at least 50% compared with baseline) among continuing smokers

    Measured: 1-, 3-, 6- and 12-months

  5. Number of quit attempts

    Self-reported intentionally no smoking for at least 24 hours

    Measured: 1-, 3-, 6- and 12-months

  6. Proportion of smokers visit smoking cessation clinics or call the telephone quitlines

    Proportion of smokers visit smoking cessation clinics or call the telephone

    Measured: 1-, 3-, 6- and 12-months

  7. Body weight

    Body weight

    Measured: 1-, 3-, 6- and 12-month FU

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2015 (estimated)
  2. Study startAug 2014
  3. Primary completionOct 2017
  4. Study completionDec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
13,671 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02494960
Sponsor's protocol ID
MegaRCT
Status last verified
Dec 2018
First submitted
8 Jul 2015
Last updated
14 Dec 2018
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing The brief smoking cessation AWARD model in people with Smoking, run by The University of Hong Kong at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Smokers' self-reported 7-day point prevalence quitting rate (time frame: up to 12-months follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2018; AzTrials last refreshed its copy on 5 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in